You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
10 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has granted Priority Review to its supplemental application for Enspryng (...
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
10 September 2026 - Seismic Pharmaceuticals, a biotechnology company focused on advancing novel treatments for heart failure, announced on Wednesday the enrolment of the first patient in its global Phase 3 clinical trial evaluating istaroxime in pati...
10 September 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Wednesday that it has dosed the first patient with rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial at Peki...
9 September 2026 - Biotechnology company Tyra Biosciences Inc (Nasdaq: TYRA) reported on Wednesday that its initial Phase 2 SURF302 results for oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder c...
9 September 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) reported on Wednesday that its partner company Solstice Oncology has launched with a USD225m Series A financing led by RA Capital Management, with participation from Canaan Par...
9 September 2026 - Oncology-focused biotechnology company Kazia Therapeutics Limited (NASDAQ: KZIA) declared on Monday that the first patient has been dosed in the Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib plus gemcitabine in pa...
9 September 2026 - Life sciences and diagnostics company Revvity Inc (NYSE:RVTY) announced on Wednesday that it has agreed to acquire France-based biotechnology company Human Cell Design (HCD), strengthening its portfolio of human-relevant cell model...